9 results about "Cinobufagin" patented technology

The invention discloses a load ICGamp. The invention discloses ZIF-8 nano-particles of CBF, and belongs to the technical field of preparation of nano-drug particles. The multifunctional nanoparticles are formed by simultaneously encapsulating indocyanine green (ICG) and cinobufagin (CBF) components by ZIF-8, and the drug loading capacities of the two drugs are both not lower than 5%. The preparation method comprises the following steps: slowly adding a solution containing cinobufagin and zinc nitrate into a mixed solution containing indocyanine green, bovine serum albumin and 2-methylimidazole, and carrying out centrifugal filtration, washing and drying on a reaction product to obtain the cinobufagin zinc oxide. The multifunctional nano-particles prepared by a one-step synthesis method are uniform in particle size and good in stability, indocyanine green and cinobufagin are uniformly distributed in a carrier, the multifunctional nano-particles have pH and near-infrared light dual response drug release characteristics, triple synergy of chemotherapy, photothermal therapy and photodynamic therapy can be realized, and the multifunctional nano-particles are simple in preparation process and suitable for popularization and application.

The invention relates to a novel medical application of cinobufagin, and the cinobufagin is used as an N-myc protein inhibition / degradation agent and can be used for anti-tumor treatment of neuroblastoma and retinoblastoma.

The invention relates to the technical field of preparation of albumin nano-drugs, in particular to a preparation method and application of a cinobufagin and pentaline albumin nano-drug. When the cinobufagin and pentaline albumin nano-drug is prepared, albumin and cinobufagin and pentaline are stably cross-linked through a chemical cross-linking method to form the cinobufagin and pentaline albumin nano-drug with controllable particle size and stable release, and the invention further discloses application of the cinobufagin and pentaline albumin nano-drug in preparation of anti-pulmonary fibrosis drugs.

The application discloses a nanometer preparation of bufonin for treating colon cancer, which has a core-shell structure, wherein the inner core is a nanocrystal composed of bufonin and a stabilizer, and the outer shell is a pH-responsive material and a pore-forming agent; the nanometer preparation of bufonin for treating colon cancer is prepared by using the stabilizer, the bufonin and the pH-responsive material; the in-vitro dissolution characteristics of the poorly soluble drug bufonin are improved by nanometerization treatment, and the dissolution characteristics are obviously improved compared with the raw drug; the pH responsiveness of the Eudragit L-100 protects the bufadienolides in the bufonin from being destroyed by the strong acidic condition of gastric juice, thereby improving the stability and effectiveness of the drug, reducing the initial release of bufalin, cinobufagin and resibufogenin in the stomach, making the drug target the intestinal site, making the three kinds of bufonin components achieve effective and rapid synergistic release in the intestinal site, increasing the utilization rate of the drug in the intestinal tract, and being beneficial to the treatment of colon cancer.

The present application belongs to the technical field of traditional Chinese medicine quality evaluation, and relates to a quality evaluation method for cinobufagin capsules based on efficacy / toxicity synchronous analysis, which comprises the following steps: S1, screening a plurality of key efficacy / toxicity components in the cinobufagin capsules; S2, obtaining the contents of the plurality of key efficacy / toxicity components; S3, obtaining the IC 50 values of the plurality of key efficacy / toxicity components; S4, determining the weight coefficients of the plurality of key efficacy / toxicity components by using an AHP (analytic hierarchy process) method according to the IC 50 value sizes; S5, obtaining the weighted total contents of the plurality of key efficacy / toxicity components according to the contents and the weight coefficients of the plurality of key efficacy / toxicity components; and S6, comparing the weighted total contents with the clinical safety content limit to complete the quality evaluation. The method can balance the conversion relationship between the efficacy and toxicity of various components in the cinobufagin capsules, and can ensure the safety and effectiveness of the cinobufagin capsules for clinical medication by using the synchronous analysis of efficacy and toxicity.

This invention discloses a compound preparation of toad skin and its preparation method, which is made by processing dried toad skin, astragalus, and tortoise shell powder in a certain proportion. Compared with the prior art, this invention has the effects of invigorating qi and tonifying the kidney, detoxifying and relieving pain. The formulation of this invention is more reasonable, and it has significant curative effects on mid-to-late stage tumors, chronic hepatitis B and other diseases, without any toxic side effects.

The invention discloses a preparation method of a cinobufagin / ganoderan nanoparticle composite sustained-release preparation, and relates to a composite sustained-release preparation as well as a preparation method and application thereof. The invention aims to solve the problems of high toxicity and the like caused by short in-vivo half-life period and wide whole-body distribution of cinobufagin in anti-tumor application. According to the cinobufagin / ganoderan nanoparticle composite sustained-release preparation disclosed by the invention, due to introduction of gel coating, the cinobufagin / ganoderan nanoparticle composite sustained-release preparation has a more lasting sustained-release property, the treatment effect of cinobufagin can be played for a long time, toxic and side effects are reduced, the cinobufagin is prevented from being cleared by multiple organs, most of medicines act on target organs, and a very good treatment effect is achieved. The good anti-tumor effect is realized; meanwhile, the damage to organs is reduced.

The application discloses a method for extracting bufadienolides in bufonis medicinals and application thereof, and belongs to the technical field of effective component extraction of traditional Chinese medicines. The method uses a deep eutectic solvent (DES) as an extracting agent, and solves the problems of low purity of bufadienolides, poor extraction efficiency and complicated process in traditional water extraction or alcohol extraction methods by optimizing the solvent composition, material ratio and extraction process. The method has high extraction efficiency, can significantly improve the total content of bufalin, resibufogenin and cinobufagin in the extract, and is simple in process, environment-friendly and easy for large-scale industrial production, thereby providing a new approach for efficient utilization of bufonis medicinals.

The invention discloses a method for extracting toad steroid total lactone in toad medicinal materials and application of the toad steroid total lactone, and belongs to the technical field of extraction of effective components of traditional Chinese medicines. According to the method, a deep eutectic solvent (DES) is taken as an extracting agent, and the problems of low purity, poor extraction efficiency and tedious process of toad sterol total lactone in a traditional water extraction or alcohol extraction method are solved by optimizing the solvent composition, the material ratio and the extraction process. The method is high in extraction efficiency, the total content of bufalin, resibufogenin and cinobufagin in the extract can be remarkably increased, the process is simple and environmentally friendly, large-scale industrial production is easy, and a new way is provided for efficient utilization of toad medicinal materials.